Status
Conditions
Treatments
About
The purpose of this study is to use real-world evidence to validate that conduction system pacing (CSP), delivered via a Medtronic 3830 catheter-delivered lead and a Medtronic dual-chamber transvenous pacemaker, is a safe and effective alternative to biventricular pacing (BVP) in patients indicated for cardiac resynchronization therapy (CRT) to deliver cardiac physiologic pacing (CPP), as documented in the clinical literature.
Enrollment
Sex
Volunteers
Inclusion criteria
Dual-chamber CSP cohort:
BVP comparator cohort:
Exclusion criteria
Dual-chamber CSP cohort:
BVP comparator cohort:
6,000 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal